Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer ...

Confirmed overall response rate (ORR) of 50% in patients with combined positive score (CPS) ≥1, including 50% ORR in patients with low CPS (1-19) 12-month overall survival of 88% and median ...

Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical ...

The study highlights the importance of oral healthcare in cancer therapy, boosting survival rates and reducing risk by advocating for better dental practices.

Merus N.V. MRUS shares have jumped 29.9% over the past three months. The uptrend was fueled by encouraging interim results from a phase II study evaluating its bispecific antibody, petosemtamab ...

Adjusted earnings of 75 cents per share beat the Zacks Consensus Estimate of 65 cents. The company registered adjusted ...

Researchers explored changes in survival outcomes and financial strain for NSCLC patients during a time when new targeted ...

Appointments of new CEO, CFO, and seasoned business development leaders with proven track records of executing strategic transactions will position the Company to drive shareholder value and advance p ...

Our findings do not suggest high utilization of neoadjuvant chemotherapy is associated with a trade-off between perioperative and long-term outcomes,” the researchers wrote.

Post-operative chemoradiation improved survival but raised non-cancer mortality. Researchers conducted a retrospective study ...

Researchers evaluated the relative importance of phenotypic and genetic factors in predicting risk for head and neck cancer.

Researchers developed a diagnostic test based on the LIMA1-alpha protein to distinguish patients with head and neck squamous cell carcinoma who can be cured with surgery alone, without the need for ...